Press Releases :: VolitionRx Ltd (VNRX)

May 7, 2025 8:30 am EDT

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

Apr 29, 2025 8:30 am EDT

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

Mar 31, 2025 4:05 pm EDT

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Mar 28, 2025 8:00 am EDT

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Mar 27, 2025 8:30 am EDT

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Mar 26, 2025 8:00 am EDT

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

Mar 25, 2025 9:30 am EDT

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Mar 21, 2025 8:30 am EDT

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Mar 20, 2025 8:30 am EDT

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Mar 17, 2025 8:30 am EDT

Volition Proudly Sponsors the 44th ISICEM Congress

rss_feed News RSS